Author:
Szollosi Doreen E.,Mathias Clinton B.
Publisher
Springer International Publishing
Reference37 articles.
1. Abreu MT. Anti-TNF failures in Crohn’s disease. Gastroenterol Hepatol. 2011;7(1):37–9.
2. Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: I. individualized medicine based on immunopharmacological evidence. Front Immunol. 2015;6:152.
3. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;334:244–7.
4. Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2016;6(1):1–12.
5. Cessak G, Kuzawinska O, Burda A, Lis K, Wojnar M, Mirowska-Guzel D, et al. TNF inhibitors—mechanisms of action, approved and off-label indications. Pharmacol Rep. 2014;66(5):836–44.